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Abstract
Factor VIII:C, epsilon amino-caproic acid or tranexamic acid are prophylactic agents used in
preventing hemorrhage pre-operatively in patients with hemophilia A. Although hemophilia A
seems to be a factor that avoids the development of acute myocardial infarction (AMI) as it
tends to be associated with increased bleeding, it should be kept in mind that prothrombotic
agents used pre-operatively for prophylaxis may increase the risk for AMI in the presence of the
factor V Leiden mutation. In this report, we discuss the development of AMI following the use
of recombinant factor VIII and tranexamic acid for prophylaxis in a patient with known
hemophilia before a tooth extraction in conjunction with the relevant literature. (Cardiol J
2009; 16, 5: 458–461)
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Introduction
Some prophylactic agents are used pre-opera-
tively in order to avoid bleeding in patients with
hemophilia A. Such prophylactic agents include fac-
tor VIII:C (FVIII), epsilon amino-caproic acid or
tranexamic acid [1]. The present paper reports the
case of a 49 year-old male patient, previously diag-
nosed with severe hemophilia A, who developed
hyperacute inferoposterolateral and right ventricu-
lar myocardial infarction as assessed by electrocar-
diography (ECG), based on the complaints of chest
pain, agitation and perspiration by the patient fol-
lowing the use of recombinant factor VIII and tran-
examic acid for prophylaxis before a tooth extrac-
tion. Based on this experience, thrombotic compli-
cations, which may rarely develop during the factor
replacement therapies in patients with hemophilia A,
were studied and reviewed in conjunction with the
literature.
Case report
The 49 year-old male was diagnosed with se-
vere hemophilia A when his FVIII level was found
to be less than 1% on examination as a result of
a history of intra-articular hemorrhage when he was
one year old. The patient consistently described oral
mucous and intra-articular hemorrhage from time
to time. He received prophylactic tranexamic acid
cap 20 mg/kg/day for ten days before the tooth
extraction, followed by recombinant FVIII 40 U/kg
immediately prior to extraction.
Initially manifesting stress resulting from agi-
tation and perspiration before the tooth extraction,
followed by chest pain, the patient presented to the
emergency service after three hours of pain. Dur-
ing the physical examination, the findings for car-
diovascular system except ECG, respiratory system
and gastrointestinal system were normal. The ECG
findings of ST elevation at DII-DIII-aVF, ST depres-
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sion at V1 and V2 and ST elevation at V4 on the right
derivations resulted in admission to the coronary
intensive care unit. He was diagnosed with hyper-
acute inferoposterolateral and right ventricular
myocardial infarction. The biochemical results were
as follows — urea: 26 mg/dL, creatinine: 1.0 mg/dL,
cholesterol: 187 mg/dL, triglycerides: 155 mg/dL,
LDL cholesterol: 130 mg/dL, ALT: 38 U-L, AST:
154 U-L, LDH: 392 U-L, and CK-MB: 170 U-L.
A complete blood count showed white blood cell:
13 × 109/L, hematocrit: 40.3%, hemoglobine:
14.2 g/dL and platelet 363 × 109/L. The patient did
not undergo any invasive intervention as percuta-
neous transluminal coronary angioplasty (PTCA) is
not available in our center and it would have taken
time to transfer him to another hospital. The coagu-
lation results were as follows — PT: 13 sn (normal
value: 12–15), APTT: 82 sn (normal value: 20–40).
No thrombolytic agent (such as streptokinase, t-PA)
was given to the patient as it increases mortality
in patients with hemostatic defects such as hemo-
philia A. Therefore, he started to receive enoxaparin
100 IU/kg SC twice a day, acetyl salicylic acid (ASA)
100 mg/day, metoprolol 50 mg/day, and atorvasta-
tin 20 mg/day PO. The levels of anticardiolipin an-
tibodies IgM (–), IgG (–), ANA (–), antidsDNA (–),
and protein C, protein S, antithrombin III and ho-
mocysteine, which were monitored in the patient
with no risk factors other than smoking for arterial
thrombosis, were found to be normal. Genotyping
from the genomic DNA of the patient revealed that
he had no prothrombin gene 20210 G > A mutation,
and investigation of factor V Leiden 1691 G > A
mutation by polymerase chain reaction (PCR) re-
vealed that he had heterozygous (+) active protein C
resistance (factor V Leiden mutation). His family
story was that his father had died from colon carci-
noma, his mother had no disease other than being
a carrier for hemophilia A and his brother had he-
mophilia A. His uncle (mother’s brother) had he-
mophilia A and died of lung cancer. Living members
of his family have no thrombosis and no factor V
Leiden mutation.
His FVIII level was controlled, and he underwent
coronary angiography using recombinant FVIII
50 U/kg. During the coronary angiography, a stent
was implanted at right coronary artery (RCA). The
patient had 40% stenosis at the S1 bifurcation of the
left anterior descending artery (LAD) and 90% at
the medial of the RCA proximal, and was discharged
from hospital with ASA 100 mg/day and clopidogrel
75 mg/day PO. During the follow-up by the cardiolo-
gy and hematology polyclinics, ASA was discontinu-
ed because of the spontaneous hemorrhage of the
oral mucosa, and maintenance of clopidogrel treat-
ment for nine months was recommended. No com-
plication was observed in the patient, who was fol-
lowed-up for approximately six months (Figs. 1, 2).
Figure 1. Coronary angiography of the right coronary
artery in the patient; upon first visualization, the vessel
is proximally occluded.
Figure 2. Coronary angiography of the right coronary
artery in the patient; after stent placement, the right
coronary artery is fully patent again with good periph-
eral blood flow.
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Discussion
Hemophilia A is an X-linked congenital bleed-
ing disorder caused by FVIII deficiency. No deterio-
ration is observed in platelet functions in this dis-
ease. It manifests with bleeding into the soft tissue
in 1/10,000 men. There is a close correlation be-
tween FVIII activity and the clinical significance of
hemorrhage. The spontaneous bleeding in patients
with a FVIII activity < 1% is associated with serious
symptoms, while the frequency of bleeding episode
is lower in patients with a FVIII activity of 1 to 5%.
If it is more than 5%, the disease takes a mild course,
and the bleeding is secondary to traumas [1]. Coro-
nary artery disease and related mortality have been
reported very rarely in hemophiliacs compared to
the normal population [2]. Some American and Eu-
ropean studies compared the mortality rates for
ischemic heart disease between patients with he-
mophilia and the general population, and found that
the mortality rate was lower in hemophiliacs than
the general population [3]. Circulatory disease in-
cluding acute myocardial infarction (AMI) has been
reported as the second most common cause of death
in patients with hemophilia in the screening stud-
ies conducted between 1995 and 1998 in the USA
[4]. It has been reported that thrombotic complica-
tions develop in patients with hemophilia, usually
following the factor replacement therapies [5]. Also
in the case we present, AMI is observed after fac-
tor replacement.
Prothrombin complex concentrate which may
be used for the treatment of bleeding in patients
with hemophilia has a thrombogenic potential.
Thrombosis usually occurs in the presence of con-
ditions requiring long-term immobilization such as
a surgical operation or underlying cardiovascular
disease as well as the presence of related risk fac-
tors when high doses of prothrombin complex con-
centrates are used [6]. Following the infusion of
recombinant FVIII, an occlusion was detected at
LAD in the coronary angiography of a patient who
had a severe chest pain with a subsequent varia-
tion observed in the anterior derivation during the
ECG [1]. It has been reported that treatment by
prothrombin complex concentrate and desmopressin
triggered AMI in a patient with hemophilia A [7].
Furthermore, various thromboembolic events such
as pulmonary embolism, deep vein thrombosis and
amaurosis fugax were reported with factor concen-
trate replacement therapy [8].
Recently, two prothrombotic molecular defects
were defined in the general population: factor V
Leiden mutation and G20210A prothrombin gene
mutation [9]. It has been reported that these mo-
lecular defects, when accompanied with severe
hemophilia A, delay onset of the bleeding symp-
toms, which substantially alter the clinical effects
of the disease, and may result in reduction in the
bleeding episodes [9]. Furthermore, thrombotic
events were previously defined in patients with
hemophilia A, and the factor V Leiden mutation was
demonstrated in these patients [10]. Although both
mutations may increase the risk of venous throm-
bosis, Rosendaal et al. [3] proposed that pro-
thrombin gene mutation is a risk factor for coronary
artery disease. In a study by Mansourati et al. [11],
it was shown that the prevalance of factor V Leiden
mutation was higher in patients with MI compared
to the control group.
In hemophiliacs who had AMI, percutaneous
transluminal coronary angioplasty (PTCA) is safer
than other methods of myocardial revascularization,
with a mortality rate of 0.9%. Following PTCA, dis-
section, occlusion, spasm, emboli and rupture were
reported in 13% of patients [12]. Experience with
coronary stents is limited in patients with hemo-
philia [1]. After PTCA, antiplatelet agents may be
required, so the risk of hemorrhage is high in pa-
tients with severe hemophilia [13]. Some studies
showed that ASA was associated with increased
hemorrhagic diathesis in hemophiliacs [14].
Although ASA plus clopidogrel may increase the
risk of bleeding, it has been shown that these agents
were effective in preventing subacute stent throm-
bosis and did not increase the risk of bleeding so
that they are recommended in patients with hemo-
philia who underwent stent implantation [15]. Re-
cently, the combination of aspirin and clopidogrel
provided more reliable and effective results than the
combination of aspirin and ticlopidin [1].
As an alternative method, coronary artery by-
pass was performed in hemophiliacs for myocardial
revascularization. However, post-operative bleed-
ing is a significant cause of mortality in patients with
hemophilia in coronary bypass operations [16].
Therefore, it is likely that PTCA is superior to coro-
nary artery bypass grafting [1].
In our hemophilia A case, the research carried
out due to development of arterial thrombotic com-
plication following the use of tranexamic acid and
factor VIII concentrate, showed that only smoking
was present among the known risk factors for arte-
rial thrombosis. However the patient was hetero-
zygous for the factor V gene 1691 G > A mutation.
Although the role of factor V Leiden mutation is
controversial in arterial thrombosis, it may increase
the development of thrombosis in those patients.
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Finally, in severe hemophiliacs, thromboem-
bolic complications may rarely occur during factor
replacement therapy. In our case, smoking and the
presence of factor V Leiden mutation, may have
contributed to the development of acute myocar-
dial infarction.
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